Xilio Therapeutics Inc XLO
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2021-10-22 |
| Shares Out. | 5,980,000 |
| Website | xiliotx.com/ ↗ |
| Phone | 13026587581 |
| Employees | 76 |
| Revenue | $18.7M |
| Gross Profit | $18.7M |
| Net Income | -$6.4M |
| Free Cash Flow | -$61.3M |
| Total Assets | $154.3M |
| Total Liabilities | $82.0M |
| Equity | $72.3M |
About Xilio Therapeutics Inc
Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.
Xilio Therapeutics Inc is a publicly traded company under the ticker symbol XLO on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
5 analysts (2026-09-01)